Literature DB >> 26252572

Biomechanical analysis of engineered bone with anti-BMP2 antibody immobilized on different scaffolds.

Sahar Ansari1, Jin-Ho Phark2, Sillas Duarte2, Maike Paulino da Silva3, Navid Sharifzadeh4, Alireza Moshaverinia1, Homayoun H Zadeh5.   

Abstract

Recently we have demonstrated the ability of monoclonal antibodies (mAb) specific for bone morphogenetic protein (BMP)-2 immobilized on different scaffolds to mediate bone formation, a process referred to as Antibody Mediated Osseous Regeneration (AMOR). One of the key properties of regenerated bone is its biomechanical strength, in particular in load-bearing areas. This study sought to test the hypothesis that the biomechanical strength of regenerated bone depends of the mode of regeneration, as well as the scaffold used. Four different scaffolds, namely titanium granules (Ti), alginate hydrogel, anorganic bovine bone mineral (ABBM), and absorbable collagen sponge (ACS) were functionalized with anti-BMP-2 or isotype control mAb and implanted into rat critical-size calvarial defects. The morphology, density and strength of the regenerated bone were evaluated after 8 weeks. Results demonstrated that scaffolds functionalized with anti-BMP-2 mAb exhibited varying degrees of bone volume and density. Ti and ABBM achieved the highest bone volume, density, and strength of bone. When anti-BMP-2 mAb was immobilized on Ti or ABBM, the strength of the regenerated bone were 80% and 77% of native bone respectively, compared with 60% of native bone in sites implanted with rh-BMP-2. Control interventions with isotype mAb did not promote considerable bone regeneration and exhibited significantly lower mechanical properties. SEM analysis showed specimens immobilized with anti-BMP-2 mAb formed new bone with organized structure bridging the crack areas. Altogether, the present data demonstrated that the morphological and mechanical properties of bone bioengineered through AMOR could approximate that of native bone, when appropriate scaffolds are used.
© 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 104B: 1465-1473, 2016. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  antibody-mediated bone regeneration; biomaterials; bone morphogenetic protein; mechanical properties; monoclonal antibody; tissue engineering

Mesh:

Substances:

Year:  2015        PMID: 26252572      PMCID: PMC4744810          DOI: 10.1002/jbm.b.33492

Source DB:  PubMed          Journal:  J Biomed Mater Res B Appl Biomater        ISSN: 1552-4973            Impact factor:   3.368


  31 in total

1.  Biological activity of rhBMP-2 released from PLGA microspheres.

Authors:  J B Oldham; L Lu; X Zhu; B D Porter; T E Hefferan; D R Larson; B L Currier; A G Mikos; M J Yaszemski
Journal:  J Biomech Eng       Date:  2000-06       Impact factor: 2.097

2.  BMP2, but not BMP4, is crucial for chondrocyte proliferation and maturation during endochondral bone development.

Authors:  Bing Shu; Ming Zhang; Rong Xie; Meina Wang; Hongting Jin; Wei Hou; Dezhi Tang; Stephen E Harris; Yuji Mishina; Regis J O'Keefe; Matthew J Hilton; Yongjun Wang; Di Chen
Journal:  J Cell Sci       Date:  2011-10-07       Impact factor: 5.285

Review 3.  Tissue engineering with recombinant human bone morphogenetic protein-2 for alveolar augmentation and oral implant osseointegration: experimental observations and clinical perspectives.

Authors:  Ulf M E Wikesjö; Giuseppe Polimeni; Mohammed Qahash
Journal:  Clin Implant Dent Relat Res       Date:  2005       Impact factor: 3.932

Review 4.  Somatic generation of antibody diversity.

Authors:  S Tonegawa
Journal:  Nature       Date:  1983-04-14       Impact factor: 49.962

5.  Bone regeneration potential of stem cells derived from periodontal ligament or gingival tissue sources encapsulated in RGD-modified alginate scaffold.

Authors:  Alireza Moshaverinia; Chider Chen; Xingtian Xu; Kentaro Akiyama; Sahar Ansari; Homayoun H Zadeh; Songtao Shi
Journal:  Tissue Eng Part A       Date:  2013-11-06       Impact factor: 3.845

6.  Antibody-mediated osseous regeneration: a novel strategy for bioengineering bone by immobilized anti-bone morphogenetic protein-2 antibodies.

Authors:  Marcelo O Freire; Huyng-Keun You; Joong-Ki Kook; Jeong-Ho Choi; Homayoun H Zadeh
Journal:  Tissue Eng Part A       Date:  2011-08-26       Impact factor: 3.845

7.  Biomechanical evaluation of rat skull defects, 1, 3, and 6 months after implantation with osteopromotive substances.

Authors:  Leigh Jones; Jesper Skovhus Thomsen; Lis Mosekilde; Carles Bosch; Birte Melsen
Journal:  J Craniomaxillofac Surg       Date:  2007-10-24       Impact factor: 2.078

8.  The effect of recombinant human bone morphogenetic protein-2 on the osteogenic potential of rat mesenchymal stem cells after several passages.

Authors:  Hisato Ishikawa; Hiroshi Kitoh; Fumiaki Sugiura; Naoki Ishiguro
Journal:  Acta Orthop       Date:  2007-04       Impact factor: 3.717

Review 9.  Bone tissue engineering: a review in bone biomimetics and drug delivery strategies.

Authors:  Joshua R Porter; Timothy T Ruckh; Ketul C Popat
Journal:  Biotechnol Prog       Date:  2009 Nov-Dec

10.  Bone regeneration in strong porous bioactive glass (13-93) scaffolds with an oriented microstructure implanted in rat calvarial defects.

Authors:  Xin Liu; Mohamed N Rahaman; Qiang Fu
Journal:  Acta Biomater       Date:  2012-08-23       Impact factor: 8.947

View more
  2 in total

1.  Antibody-Mediated Osseous Regeneration for Bone Tissue Engineering in Canine Segmental Defects.

Authors:  A Khojasteh; S Hosseinpour; M M Dehghan; F Mashhadiabbas; M Rezai Rad; S Ansari; S Farzad Mohajeri; H H Zadeh
Journal:  Biomed Res Int       Date:  2018-02-28       Impact factor: 3.411

2.  Functionalized Scaffold and Barrier Membrane with Anti-BMP-2 Monoclonal Antibodies for Alveolar Ridge Preservation in a Canine Model.

Authors:  Seiko Min; Taewan Kim; Oksu Kim; Carames Goncalo; Tadahiko Utsunomiya; Takashi Matsumoto; Kayo Kuyama; Nikola Angelov
Journal:  Biomed Res Int       Date:  2020-09-22       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.